Canterbury DHB


Management of elderly patients with lymphoma

There is debate over the upper age limit of treatment for lymphoma and especially aggressive non-Hodgkin’s lymphoma. Elderly could be used to define patients by age, e.g. over 70 or 75 years, or by function, i.e. those who are not expected to undergo standard chemotherapy without excessive risk. CHOP chemotherapy may be dose reduced in older or frailer patients and become more tolerable while retaining some valuable efficacy. See Peyrade, F., et al. (2011). "Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial." Lancet Oncol 12(5): 460-468.

Further reading

Peyrade, F., et al. (2012). "Treatment decisions for elderly patients with haematological malignancies: a dilemma." Lancet Oncol 13(8): e344-e352

About this Canterbury DHB document (33790):

Document Owner:

Peter Ganly (see Who's Who)

Last Reviewed:

November 2018

Next Review:

November 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 33790